Hoth Therapeutics, INC

Rocket One Inc. announced an increase in its At-The-Market offering, potentially raising an additional $5.26 million.

Rocket One Inc. announced a strategic collaboration with Placeve Inc. and shared updated presentation materials detailing its AI semiconductor infrastructure development for defense, space, and edge computing.

Rocket One Inc. has officially regained compliance with Nasdaq's minimum bid price requirement after maintaining a closing price above $1.00 for ten consecutive business days.

Rocket One Inc. announced the appointment of Major General Malcolm B. Frost (Ret.) to its Space and Defense Advisory Board to guide technical development in AI computing and memory hardware for space and defense.

Rocket One Inc. has increased its At-The-Market offering by up to an additional $6.83 million, supplementing shares already sold.

Rocket One Inc. has appointed Dr. Supriyo Bandyopadhyay as Lead Technical Advisor for its AI Nanomagnetic Technology, aiming to advance its space and defense computing hardware.

Hoth Therapeutics reported a wider net loss in Q3 2025 due to increased R&D and administrative expenses, while securing additional capital through warrant exercises and an ATM offering.

Hoth Therapeutics reported a significant increase in net loss for Q2 2025, driven by higher research and development expenses, while bolstering its cash position through financing activities.

Hoth Therapeutics reports a net loss for Q1 2025, but strengthens its cash position through warrant exercises and ATM offerings.

Hoth Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting ongoing research and development efforts and a decrease in net loss compared to the same period last year.

Hoth Therapeutics reports a net loss of $3.7 million for the six months ended June 30, 2024, with a decrease in research and development expenses and an increase in general and administrative costs.

Hoth Therapeutics reported a net loss of $2.0 million for the first quarter of 2024, with a focus on advancing its clinical-stage biopharmaceutical programs.

Hoth Therapeutics, Inc. reported a significant increase in net loss for 2025, alongside a going concern warning from its auditors, despite progress in its clinical pipeline and substantial capital raises.

Hoth Therapeutics restates prior financial statements due to material errors in R&D expense recognition, while continuing to advance its pipeline and seek new opportunities.

Hoth Therapeutics details a warrant agreement and its 2023 financial results, highlighting ongoing clinical trials and future development plans.

Director Wayne Linsley was granted 75,000 stock options in Rocket One Inc. as part of the company's equity incentive plan.

Director David Sarnoff was granted 75,000 stock options in Rocket One Inc. on May 26, 2026.

Director Christopher Michael Camarra was granted 75,000 stock options in Rocket One Inc. on May 26, 2026.

Director Jeff Pavell was granted 75,000 stock options in Rocket One Inc. on May 26, 2026.

Hoth Therapeutics CEO Robb Knie acquired 800,000 shares of common stock and disposed of 310,744 shares for tax purposes.

Hoth Therapeutics CEO Robb Knie reports the acquisition of 100,000 options in the company, vesting immediately.

Hoth Therapeutics, Inc. has filed definitive additional proxy materials for its 2025 Annual Meeting of Shareholders, seeking votes on the election of directors, ratification of its accounting firm, and an increase in shares reserved for its equity incentive plan.

Hoth Therapeutics, Inc. announced its 2025 Annual Meeting of Shareholders to be held virtually on August 5, 2025, where key proposals include the election of directors, ratification of auditors, and a significant increase in shares reserved for its equity incentive plan.

Hoth Therapeutics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Hoth Therapeutics is holding its annual shareholder meeting on August 7, 2024, to vote on director elections, ratify the appointment of its accounting firm, and approve an amendment to its equity incentive plan.

Hoth Therapeutics is registering for the resale of up to 5,030,000 shares of common stock by selling stockholders, potentially generating $9.49 million in gross proceeds upon warrant exercises.